Literature DB >> 23449457

TGF-β1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death.

J Park1, J Lee, W Kang, S Chang, E-C Shin, C Choi.   

Abstract

Sporadic occurrence of transformed tumor cells is under the surveillance of the host immune system and such cells are effectively eliminated by immune-mediated cell death. During tumor progression, the antitumor effects of the tumor microenvironment are suppressed by diverse immunosuppressive mechanisms. In this research, we suggest novel immune evasion strategy of tumor cells through a transforming growth factor (TGF)-β1- and hypoxia-dependent mechanism. Experimental results showed that TGF-β1 and hypoxia induced mitogen-activated protein kinase phosphatase (MKP)-1 expression within 1 h, resulting in attenuation of c-Jun N-terminal kinase (JNK) phosphorylation and subsequent death receptor-mediated cell death. In addition, analysis of microarray data and immunostaining of MKP-1 in hepatocellular carcinoma (HCC) patient samples revealed that expression of MKP-1 is notably higher in tumors than in normal tissues, implying that MKP-1-dependent suppression of immune-mediated cell death takes place only in the tumor. To prove that MKP-1 can act as a mediator of immune escape by tumors, we determined whether chemo-resistance against several anticancer drugs could be overcome by knockdown of MKP-1. Cytotoxic assays showed that chemotherapy with siRNA targeting MKP-1 was significantly more effective than chemotherapy in the presence of MKP-1. Thus, we conclude that TGF-β1 and hypoxia ensure tumor cell survival and growth through expression of MKP-1.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23449457      PMCID: PMC3734814          DOI: 10.1038/cddis.2013.42

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  39 in total

Review 1.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

Authors:  Li Yang; Yanli Pang; Harold L Moses
Journal:  Trends Immunol       Date:  2010-06-01       Impact factor: 16.687

Review 2.  A fresh look at tumor immunosurveillance and immunotherapy.

Authors:  M J Smyth; D I Godfrey; J A Trapani
Journal:  Nat Immunol       Date:  2001-04       Impact factor: 25.606

Review 3.  Activation of the JNK signaling pathway: breaking the brake on apoptosis.

Authors:  Anning Lin
Journal:  Bioessays       Date:  2003-01       Impact factor: 4.345

Review 4.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 5.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

6.  Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2.

Authors:  Suntaek Hong; Seunghwan Lim; Allen G Li; Chan Lee; Youn Sook Lee; Eun-Kyung Lee; Seok Hee Park; Xiao-Jing Wang; Seong-Jin Kim
Journal:  Nat Immunol       Date:  2007-03-25       Impact factor: 25.606

Review 7.  Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases.

Authors:  D M Owens; S M Keyse
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 8.  TGF-beta and tumors--an ill-fated alliance.

Authors:  Niki M Moutsopoulos; Jie Wen; Sharon M Wahl
Journal:  Curr Opin Immunol       Date:  2008-05-15       Impact factor: 7.486

9.  Smad7 sensitizes tumor necrosis factor induced apoptosis through the inhibition of antiapoptotic gene expression by suppressing activation of the nuclear factor-kappaB pathway.

Authors:  Suntaek Hong; Chan Lee; Seong-Jin Kim
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

10.  A JNK-dependent pathway is required for TNFalpha-induced apoptosis.

Authors:  Yibin Deng; Xiaoyang Ren; Lin Yang; Yahong Lin; Xiangwei Wu
Journal:  Cell       Date:  2003-10-03       Impact factor: 41.582

View more
  7 in total

1.  Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression.

Authors:  Lei Zhao; B O Jiang; Dong Wang; Wei Liu; Huawu Zhang; Weisheng Liu; Zhen Qiu
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

2.  A single nucleotide polymorphism in the TGF-β1 gene (rs1982073 C>T) may contribute to increased risks of bone fracture, osteoporosis, and osteoarthritis: a meta-analysis.

Authors:  Yu Cong; Jiang-Ying Ru; Ni-Rong Bao; Ting Guo; Jian-Ning Zhao
Journal:  Clin Rheumatol       Date:  2014-12-13       Impact factor: 2.980

3.  Family with sequence similarity 46 member a confers chemo-resistance to ovarian carcinoma via TGF-β/Smad2 signaling.

Authors:  Suiying Liang; Yueyang Liu; Jianhui He; Tian Gao; Lanying Li; Shanyang He
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

4.  Phenotypic modulation of primary vascular smooth muscle cells by short-term culture on micropatterned substrate.

Authors:  Soyoung Chang; Seungjeong Song; Jungsul Lee; Jonghee Yoon; Junseong Park; Sungyoung Choi; Je-Kyun Park; Kyungsun Choi; Chulhee Choi
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 5.  Regulatory Roles of MAPK Phosphatases in Cancer.

Authors:  Heng Boon Low; Yongliang Zhang
Journal:  Immune Netw       Date:  2016-04-28       Impact factor: 6.303

6.  GLIS2 redundancy causes chemoresistance and poor prognosis of gastric cancer based on co‑expression network analysis.

Authors:  Jingsheng Yuan; Lulu Tan; Zhijie Yin; Kaixiong Tao; Guobing Wang; Wenjia Shi; Jinbo Gao
Journal:  Oncol Rep       Date:  2018-10-15       Impact factor: 3.906

Review 7.  Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy.

Authors:  Jiliang Shen; Yaping Zhang; Hong Yu; Bo Shen; Yuelong Liang; Renan Jin; Xiaolong Liu; Liang Shi; Xiujun Cai
Journal:  Cancer Med       Date:  2016-05-26       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.